In 2009, the American Thyroid Association (ATA) revised its guidelines to add that doctors may consider the use of molecular markers when the initial biopsy is inconclusive.
When the molecular imaging research community improves image standardization, there is a greater likelihood of harmonization; i.e., that a specific imaging procedure can be used as a marker across clinical trials; not simply for one clinical trial.